Narrative Review: Efficacy, Safety, and Tolerability of Newer Third-Generation Antiseizure Medications for Focal Epilepsy: A New Benchmark in Treatment Outcomes? (PubMed, Neurol Ther) - Sep 1, 2026 - "All third-generation ASMs were effective adjunctive therapies. Cenobamate was associated with higher responder and seizure freedom rates and higher long-term retention rates. Brivaracetam and lacosamide had favorable tolerability profiles. The notable seizure freedom rates with cenobamate suggest a potential new benchmark in focal seizure treatment. Comparator trials are needed to confirm possible efficacy and tolerability differences among third-generation ASMs."
Journal • Review • CNS Disorders • Eosinophilia • Epilepsy • Fatigue • Pain • Psychiatry
|
|
Louis Ferrari; Pavel Klein; Vicente Villanueva; William E Rosenfeld
|